A1 Journal article – refereed

99mTc-labeled rHuEpo for imaging of the erythropoietin receptor in tumors




List of Authors: Zhuang XQ, Zhao D, Yang PF, Jia YQ, Liang R, Zhao Q, Han CL, Kinsella JM, Sheng RL, Li J

Publisher: WILEY

Publication year: 2018

Journal: Journal of Labelled Compounds and Radiopharmaceuticals

Journal name in source: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Journal acronym: J LABELLED COMPD RAD

Volume number: 61

Issue number: 2

Number of pages: 7

ISSN: 0362-4803

eISSN: 1099-1344

DOI: http://dx.doi.org/10.1002/jlcr.3586


Abstract
To analyze erythropoietin receptor (EpoR) status in tumors, recombinant human erythropoietin (rHuEpo) was labeled with Tc-99m by Tc-99m-centered 1-pot synthesis, resulting in high radiochemical purity, stability, and biological activity. Both in vitro cell culture experiments and biodistribution studies of normal rats demonstrated successful EpoR targeting. The biodistribution of labeled rHuEpo in a NCI-H1975 xenograft model showed tumor accumulation (tumor-to-muscle ratio, 4.27 +/- 1.77), confirming the expression of active EpoR in tumors. Thus, as a novel single positron emission computerized tomography tracer for the imaging of EpoR expression in vivo, Tc-99m-rHuEpo is effective for exploring the role of EpoR in cancer growth, metastasis and angiogenesis.


Last updated on 2021-24-06 at 11:04